Leuthold Group LLC Sells 87 Shares of Elevance Health, Inc. (NYSE:ELV)

Leuthold Group LLC lessened its holdings in Elevance Health, Inc. (NYSE:ELV) by 0.6% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,118 shares of the company’s stock after selling 87 shares during the period. Leuthold Group LLC’s holdings in Elevance Health were worth $7,839,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in ELV. MGB Wealth Management LLC purchased a new position in shares of Elevance Health during the first quarter worth about $377,000. Manchester Capital Management LLC lifted its position in Elevance Health by 5.3% during the first quarter. Manchester Capital Management LLC now owns 875 shares of the company’s stock valued at $454,000 after purchasing an additional 44 shares during the last quarter. Oxbow Advisors LLC grew its stake in Elevance Health by 0.6% in the 1st quarter. Oxbow Advisors LLC now owns 10,538 shares of the company’s stock worth $5,464,000 after buying an additional 63 shares in the last quarter. Advisory Alpha LLC increased its holdings in shares of Elevance Health by 68.1% in the 1st quarter. Advisory Alpha LLC now owns 955 shares of the company’s stock worth $495,000 after buying an additional 387 shares during the last quarter. Finally, Mitchell Capital Management Co. raised its position in shares of Elevance Health by 0.9% during the 1st quarter. Mitchell Capital Management Co. now owns 7,253 shares of the company’s stock valued at $3,761,000 after buying an additional 66 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 0.4 %

Shares of Elevance Health stock traded up $2.26 during midday trading on Friday, hitting $536.08. The company had a trading volume of 387,125 shares, compared to its average volume of 1,007,511. Elevance Health, Inc. has a 52-week low of $414.79 and a 52-week high of $550.34. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.37 and a current ratio of 1.37. The stock has a market capitalization of $124.60 billion, a P/E ratio of 20.17, a P/E/G ratio of 1.18 and a beta of 0.84. The company has a 50 day moving average of $534.30 and a 200 day moving average of $512.43.

Elevance Health (NYSE:ELV) last released its earnings results on Thursday, April 18th. The company reported $10.64 EPS for the quarter, topping analysts’ consensus estimates of $10.54 by $0.10. The firm had revenue of $42.27 billion for the quarter, compared to analysts’ expectations of $42.49 billion. Elevance Health had a return on equity of 20.62% and a net margin of 3.64%. The company’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $9.46 earnings per share. On average, equities analysts predict that Elevance Health, Inc. will post 37.25 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 25th. Shareholders of record on Monday, June 10th were paid a dividend of $1.63 per share. The ex-dividend date was Monday, June 10th. This represents a $6.52 dividend on an annualized basis and a yield of 1.22%. Elevance Health’s dividend payout ratio is currently 24.64%.

Insiders Place Their Bets

In related news, EVP Felicia F. Norwood sold 14,111 shares of the firm’s stock in a transaction that occurred on Tuesday, April 23rd. The shares were sold at an average price of $533.74, for a total transaction of $7,531,605.14. Following the completion of the sale, the executive vice president now owns 31,460 shares of the company’s stock, valued at $16,791,460.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ELV shares. Mizuho increased their target price on Elevance Health from $575.00 to $585.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. StockNews.com lowered Elevance Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 6th. Royal Bank of Canada boosted their target price on Elevance Health from $574.00 to $575.00 and gave the stock an “outperform” rating in a research report on Friday, April 19th. UBS Group increased their price target on shares of Elevance Health from $585.00 to $605.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Finally, Bank of America boosted their price objective on shares of Elevance Health from $621.00 to $646.00 and gave the stock a “buy” rating in a report on Tuesday, June 4th. One analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $611.36.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.